Enter your email address:

Delivered by FeedBurner

Pain for big Indian pharma companies continue warns CRISIL, as FDA woes remains unresolved

Indian drug makers in the last few years have diversified their
portfolio towards complex generics in an attempt to insulate
themselves from pricing pressure in the US. The complex generic
pipeline of Indian generic makers stands at 25%, it is this pipeline
that is expected to pump up the sales numbers for Indian companies.



Post a Comment